SCHEMBL6038896

SCHEMBL6038896

Cc1ccccc1S(=O)(=O)Nc1nc2ccccc2nc1OCc1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 2/20 0.56
ALDH1A1 P00352 4/20 0.53
RXFP1 Q9HBX9 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TP53 P04637 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HRH4 Q9H3N8 1/20 0.47
PKM P14618 2/20 0.46
TSHR P16473 2/20 0.44
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
NCOA1 Q15788 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PLA2G1B P04054 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039025 0.89 ALDH1A1 (0.50) CCR4ALDH1A1RXFP1L3MBTL1TP53
SCHEMBL6038895 0.88 ALDH1A1 (0.56) CCR4ALDH1A1RXFP1L3MBTL1TP53
SCHEMBL3293600 0.87 CCR4 (0.64) CCR4ALDH1A1RXFP1L3MBTL1KDM4E
SCHEMBL2427956 0.87 CCR4 (0.57) CCR4TP53KDM4ELMNAHSD17B10
SCHEMBL6038910 0.85 KDM4E (0.56) CCR4ALDH1A1KDM4EHPGDLMNA
SCHEMBL2424076 0.85 CCR4 (0.77) CCR4
SCHEMBL6039136 0.85 KDM4E (0.63) CCR4ALDH1A1RXFP1TDP1KDM4E
SCHEMBL2424987 0.83 CCR4 (0.54) CCR4ALDH1A1KDM4ELMNAHSD17B10
SCHEMBL6039603 0.83 KDM4E (0.53) CCR4ALDH1A1KDM4EHPGDLMNA
SCHEMBL6038395 0.82 KDM4E (0.57) CCR4RXFP1L3MBTL1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CCR4 1/4885ALDH1A1 2902/4885RXFP1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.